Last 64,900
Change Today 0.00 / 0.00%
Volume 0.0
PRGO On Other Exchanges
Symbol
Exchange
New York
Tel Aviv
Frankfurt
As of 10:24 AM 12/25/14 All times are local (Market data is delayed by at least 15 minutes).

perrigo co plc (PRGO) Snapshot

Open
$64,900
Previous Close
$64,900
Day High
$65,290
Day Low
$64,830
52 Week High
12/23/14 - $66,500
52 Week Low
05/7/14 - $44,600
Market Cap
91.4B
Average Volume 10 Days
138.4K
EPS TTM
$3.33
Shares Outstanding
140.8M
EX-Date
11/28/14
P/E TM
49.9x
Dividend
$0.42
Dividend Yield
0.23%
Current Stock Chart for PERRIGO CO PLC (PRGO)

perrigo co plc (PRGO) Details

Perrigo Company plc, through its subsidiaries, develops, manufactures, and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, nutritional products, and active pharmaceutical ingredients (API). Its Consumer Healthcare segment offers OTC pharmaceutical products in the areas of analgesics, cough/cold/allergy/sinus, gastrointestinal, smoking cessation, and animal health products, as well as in the areas of feminine hygiene, diabetes care, and dermatological care; and contract manufacturing services. The company’s Nutritionals segment offers infant and toddler formula products, infant and toddler foods, as well as vitamins, minerals, and dietary supplement products to retailers, distributors, and consumers. Its Rx Pharmaceuticals segment develops, manufactures and markets a portfolio of Rx drugs in topical dosage forms, such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions, and powders, as well as controlled substances, injectables, hormones, oral solid dosage forms, and oral liquid formulations. This segment provides its products to chain drug stores, wholesalers, distributors, hospital systems, and group purchasing organizations. The company’s API segment develops, manufactures, and markets API that are used in the production of pharmaceutical products to generic drug industries and branded pharmaceutical companies. Its Specialty Sciences segment provides Tysabri, which is used for the treatment of Multiple Sclerosis; and Prialt, a non-narcotic intrathecal analgesic. The company also offers pharmaceutical and medical diagnostic products. The company offers its products primarily in the United States, the United Kingdom, Mexico, Israel, and Australia, as well as in Canada, China, and Latin America. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

10,220 Employees
Last Reported Date: 10/1/14
Founded in 1887

perrigo co plc (PRGO) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.1M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $563.2K
Executive Vice President of Global Operations...
Total Annual Compensation: $470.3K
Executive Vice President, General Counsel and...
Total Annual Compensation: $470.3K
Executive Vice President and General Manager ...
Total Annual Compensation: $458.0K
Compensation as of Fiscal Year 2014.

perrigo co plc (PRGO) Key Developments

Perrigo Company plc Approves Change of Fiscal Year-End from the Closest to Each June 30 to December 31

The board of directors of Perrigo Company plc approved a change in the company's fiscal year-end from the closest to each June 30 to December 31. The change in fiscal year will become effective for the company's 2016 fiscal year, which will begin January 1, 2016 and end December 31, 2016.

Perrigo Company Public Limited Company(NYSE:PRGO) added to S&P 500 Value Index

Perrigo Company Public Limited Company(NYSE:PRGO) added to S&P 500 Value Index

Perrigo Company plc Amends Revolving Credit Agreement

On September 6, 2013, Perrigo Company plc entered into: a Revolving Credit Agreement (the Existing Revolving Credit Agreement), among the company, as borrower, the financial institutions listed on the signature pages thereof, Barclays Bank PLC as administrative agent for the lenders, and HSBC Bank USA, N.A. as syndication agent for the lenders, as amended on November, 19, 2014 (the Existing Revolver Amendment); and a Term Loan Credit Agreement (the Existing Term Loan Credit Agreement and, together with the Existing Revolving Credit Agreement, the Existing Credit Agreements), among the company, as borrower, the financial institutions listed on the signature pages thereof, Barclays, as administrative agent for the lenders and HSBC, as syndication agent for the lenders, as amended on November 19, 2014, (the Existing Term Loan Amendment). Effective December 5, 2014, the company terminated the Existing Credit Agreements, as amended, and replaced the Existing Credit Agreements by entering into: a new senior unsecured Revolving Credit Agreement (the New Revolving Credit Agreement), among Perrigo Finance plc, a public limited company organized under the laws of Ireland and a finance subsidiary of the company (Perrigo Finance and together with the company, the Borrowers), as borrower, the company, the financial institutions listed on the signature pages thereof, JPMorgan Chase Bank, N.A. as administrative agent for the lenders, and Barclays, as syndication agent for the lenders; and a new senior unsecured Term Loan Credit Agreement (the New Term Loan Credit Agreement and, together with the New Revolving Credit Agreement, the New Credit Agreements), among the company, as borrower under a 2-year term loan tranche (the 2-Year Tranche), Perrigo Finance, as borrower under a 5-year term loan tranche (the 5-Year Tranche), the financial institutions listed on the signature pages thereof, JPMorgan, as Administrative Agent for the lenders, and Barclays, as syndication agent for the lenders. The New Credit Agreements provide for: Revolving Facility: a $1.0 billion senior unsecured revolving line of credit (including a $50.0 million letter of credit sub-facility and a $100.0 million swingline sub-facility), maturing as of the fifth anniversary of the Effective Date, $600.0 million of which is immediately available and $400.0 million (the Acquisition Closing Date Revolving Commitments) of which will be available upon the consummation of the company's acquisition (the Acquisition) of Omega Pharma Invest NV (the Acquisition ClosingDate); 2-Year Tranche: up to $300.0 million in senior unsecured term loan financing, maturing on December 18, 2015; and 5-Year Tranche: up to 800.0 million in senior unsecured term loan financing, maturing on the fifth anniversary of the Effective Date, up to 300.0 million of which is structured as a delayed draw facility (the Delayed Draw 5-Year Tranche). The 5-Year Tranche will be subject to annual amortization equal to 10% of the original amount of the 5-Year Tranche during each of the first three years following the Effective Date, with such amounts increasing to 12.5% and 15% in years four and five, respectively. Any remaining amounts outstanding under the 5-Year Tranche will be payable in full on the maturity date. The availability of the Delayed Draw 5-Year Tranche is subject to, among other things, the consummation of the Acquisition. The proceeds from the borrowings under the New Credit Agreements will be used, among other things, to fund working capital and for other general corporate purposes, including partially to finance the Acquisition and to pay fees and expenses in connection therewith.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRGO:IT 64,900.00 0.00

PRGO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Dr Reddy's Laboratories Ltd 3,134 INR 0.00
Endo International PLC $73.16 USD +1.06
Hospira Inc $62.44 USD -0.16
Mead Johnson Nutrition Co $102.49 USD +0.45
Mylan Inc/PA $57.60 USD +0.63
View Industry Companies
 

Industry Analysis

PRGO

Industry Average

Valuation PRGO Industry Range
Price/Earnings 100.0x
Price/Sales 5.4x
Price/Book 2.5x
Price/Cash Flow 122.8x
TEV/Sales 4.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PERRIGO CO PLC, please visit www.perrigo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.